Alaunos Therapeutics (TCRT) Liabilities and Shareholders Equity (2009 - 2026)

Alaunos Therapeutics (TCRT) has 18 years of Liabilities and Shareholders Equity data on file, last reported at $1.9 million in Q1 2026.

• Quarterly Liabilities and Shareholders Equity fell 11.18% year-over-year to $1.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $13.3 million (up 1.56% YoY) and the FY2025 annual result came in at $3.0 million, up 7.66% from the prior year.
• Liabilities and Shareholders Equity fell to $1.9 million in Q1 2026, from $3.0 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $85.0 million in Q1 2022 to a low of $1.9 million in Q1 2026.
• A 5-year average of $25.2 million and a median of $6.0 million in 2024 frame the typical range for Liabilities and Shareholders Equity.
• Annual changes were most pronounced in 2024 — Liabilities and Shareholders Equity tumbled 87.59% — and 2025, when it advanced 7.66%.
• Tracing TCRT's Liabilities and Shareholders Equity over 5 years: stood at $64.9 million in 2022, then plunged by 87.28% to $8.3 million in 2023, then slumped by 66.66% to $2.8 million in 2024, then climbed by 7.66% to $3.0 million in 2025, then sank by 36.51% to $1.9 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $1.9 million (Q1 2026), $3.0 million (Q4 2025), and $3.7 million (Q3 2025), per Business Quant data.